Basic & Clinical Pharmacology & Toxicology最新文献_第8页

Safety evaluation of adenosine, lidocaine and magnesium (ALM) intranasal therapy toward human nasal epithelial cells in vitro 腺苷、利多卡因和镁（ALM）鼻内疗法对人鼻腔上皮细胞的体外安全性评估。

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-24 DOI: 10.1111/bcpt.14036

Jodie L. Morris, Hayley L. Letson, Geoffrey P. Dobson

{"title":"Safety evaluation of adenosine, lidocaine and magnesium (ALM) intranasal therapy toward human nasal epithelial cells in vitro","authors":"Jodie L. Morris, Hayley L. Letson, Geoffrey P. Dobson","doi":"10.1111/bcpt.14036","DOIUrl":"10.1111/bcpt.14036","url":null,"abstract":"Adenosine, lidocaine and Mg2+ (ALM) solution is an emerging therapy that reduces secondary injury after intravenous administration in experimental models of traumatic brain injury (TBI). Intranasal delivery of ALM may offer an alternative route for rapid, point-of-care management of TBI. As a preliminary safety screen, we evaluated whether ALM exerts cytotoxic or inflammatory effects on primary human nasal epithelial cells (pHNEC) in vitro. Submerged monolayers and air–liquid interface cultures of pHNEC were exposed to media only, normal saline only, therapeutic ALM or supratherapeutic ALM for 15 or 60 min. Safety was measured through viability, cytotoxicity, apoptosis, cellular and mitochondrial stress, and inflammatory mediator secretion assays. No differences were found in viability or cytotoxicity in cultures exposed to saline or ALM for up to 60 min, with no evidence of apoptosis after exposure to supratherapeutic ALM concentrations. Despite comparable inflammatory cytokine secretion profiles and mitochondrial activity, cellular stress responses were significantly lower in cultures exposed to ALM than saline. In summary, data show ALM therapy has neither adverse toxic nor inflammatory effects on human nasal epithelial cells, setting the stage for in vivo toxicity studies and possible clinical translation of intranasal ALM therapy for TBI treatment.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"98-108"},"PeriodicalIF":3.1,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sodium para-aminosalicylic acid attenuates combined manganese/iron-induced cortical synaptic damage in rats 对氨基水杨酸钠可减轻锰/铁联合诱导的大鼠大脑皮层突触损伤。

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-23 DOI: 10.1111/bcpt.14033

Han-Xiao Song, Yu-Han Xie, Yuan-Yuan Fang, Jun-Jie Lin, Lei-Lei Wang, Cui-liu Gan, Michael Aschner, Yue-Ming Jiang

{"title":"Sodium para-aminosalicylic acid attenuates combined manganese/iron-induced cortical synaptic damage in rats","authors":"Han-Xiao Song, Yu-Han Xie, Yuan-Yuan Fang, Jun-Jie Lin, Lei-Lei Wang, Cui-liu Gan, Michael Aschner, Yue-Ming Jiang","doi":"10.1111/bcpt.14033","DOIUrl":"10.1111/bcpt.14033","url":null,"abstract":"We established experimental models of manganese (Mn) and iron (Fe) exposure in vitro and in vivo, and addressed the effects of manganese and iron combined exposure on the synaptic function of pheochromocytoma derived cell line 12 (PC12) cells and rat cortex, respectively. We investigated the protective effect of sodium para-aminosalicylate (PAS-Na) on manganese and iron combined neurotoxicity, providing a scientific basis for the prevention and treatment of ferromanganese combined neurotoxicity. Western blot and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were performed to detect the expression levels of protein and mRNA related to synaptic damage. Y-maze novelty test and balance beam test were used to evaluate the motor and cognitive function of rats. Haematoxylin and eosin (H&E) and Nissl staining were performed to observe the cortical damage of rats. The results showed that the combined exposure of Mn and Fe in rats led to a synergistic effect, attenuating growth and development, and altering learning and memory as well as motor function. The combination of Mn and Fe also caused damage to the synaptic structure of PC12 cells, which is manifested as swelling of dendrites and axon terminals, and even lead to cell death. PAS-Na displayed some antagonistic effects against the Mn- and Fe-induced synaptic structural damage, growth, learning and memory impairment.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"81-97"},"PeriodicalIF":3.1,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation of the new peptide drug ACTY116-loaded in situ forming implants and evaluation of its efficacy in pulmonary arterial hypertension and right ventricular hypertrophy induced by SU5416/hypoxia in mice 制备新的多肽药物 ACTY116 负载原位成型植入物，并评估其对 SU5416/缺氧诱导的小鼠肺动脉高压和右心室肥大的疗效。

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-20 DOI: 10.1111/bcpt.14020

Qiao Liu, Qingman Luo, Bin Zhong, Yingxin Xiong, Xueling Chen, Xiaohui Li

{"title":"Preparation of the new peptide drug ACTY116-loaded in situ forming implants and evaluation of its efficacy in pulmonary arterial hypertension and right ventricular hypertrophy induced by SU5416/hypoxia in mice","authors":"Qiao Liu, Qingman Luo, Bin Zhong, Yingxin Xiong, Xueling Chen, Xiaohui Li","doi":"10.1111/bcpt.14020","DOIUrl":"10.1111/bcpt.14020","url":null,"abstract":"There is a lack of effective therapeutic drugs for pulmonary arterial hypertension. Previous studies have demonstrated the positive cardiovascular system protective effects of the new peptide ACTY116. However, its stability in ordinary aqueous solution injections is poor and its half-life in the body is short, which has hindered the development of preparations. This study aimed to prepare in situ forming implants (ISFIs) of the peptide ACTY116 and investigate its impact on pulmonary arterial hypertension. We prepared ISFIs using NMP/TA as a solvent and PLGA as a polymer. These ISFIs exhibited low viscosity, low toxicity and sustained release properties. In a mouse model of pulmonary hypertension induced by SU5416/hypoxia, both ISFIs and ACTY116 peptides effectively reduced pulmonary hypertension, cardiac hypertrophy and pulmonary blood vessel wall thickness. In conclusion, this study highlights the potential of ACTY116 as a treatment for pulmonary arterial hypertension and suggests that incorporating it into an in-situ gel implant could be a promising option.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"60-70"},"PeriodicalIF":3.1,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to Involvement of H2S, NO and BDNF-TrkB signalling pathway in the protective effects of simvastatin against pentylenetetrazole-induced kindling and cognitive impairments in mice 更正为辛伐他汀对戊四唑诱导的小鼠木僵和认知障碍的保护作用中H2S、NO和BDNF-TrkB信号通路的参与。

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-16 DOI: 10.1111/bcpt.14016

{"title":"Correction to Involvement of H2S, NO and BDNF-TrkB signalling pathway in the protective effects of simvastatin against pentylenetetrazole-induced kindling and cognitive impairments in mice","authors":"","doi":"10.1111/bcpt.14016","DOIUrl":"10.1111/bcpt.14016","url":null,"abstract":"\u0000 Marwa A. Ahmed, Esam O. Kamel. Involvement of H2S, NO and BDNF-TrkB signalling pathway in the protective effects of simvastatin against pentylenetetrazole-induced kindling and cognitive impairments in mice. Basic Clin Pharmacol Toxicol. (2020); 127(6): 460–476. doi:10.1111/bcpt.13457In the results section of the above article, duplications of subfigures was found in Figure 6C,D, Figure 6I,K, and Figure 7C,D. The senior authors were not aware of the errors in the figure. Therefore, the figures have now been replaced.After replacement of the wrong figures with the new corrected figures, legends are the same because there are no new depicted features and so the captions are the same, too. In addition, these new corrected figures do not affect the results or discussion and so they do not affect the final conclusion of the manuscript.Below are the correct figures.The authors apologize for this error.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"109-111"},"PeriodicalIF":3.1,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gender balance in the editorial room: BCPT as model journal? 编辑室的性别平衡：BCPT 作为示范期刊？

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-14 DOI: 10.1111/bcpt.14019

Petrine Wellendorph, Pernille Tveden-Nyborg

引用次数: 0

The mitigating effect of para-hydroxycinnamic acid in bleomycin-induced pulmonary fibrosis in mice through targeting oxidative, inflammatory and fibrotic pathways 对羟基肉桂酸通过靶向氧化、炎症和纤维化途径对博来霉素诱导的小鼠肺纤维化有缓解作用。

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-14 DOI: 10.1111/bcpt.14018

Zeena A. Hussein, Ahmed R. Abu-Raghif, Hayder Adnan Fawzi

{"title":"The mitigating effect of para-hydroxycinnamic acid in bleomycin-induced pulmonary fibrosis in mice through targeting oxidative, inflammatory and fibrotic pathways","authors":"Zeena A. Hussein, Ahmed R. Abu-Raghif, Hayder Adnan Fawzi","doi":"10.1111/bcpt.14018","DOIUrl":"10.1111/bcpt.14018","url":null,"abstract":"This study investigated the therapeutic benefits of para-hydroxycinnamic acid in mice with bleomycin-induced lung fibrosis. Forty male BALB/c mice were randomly assigned to four groups: normal, which received 0.9% normal saline; induced, which received a single dose of bleomycin (5 mg/kg) by oropharyngeal challenge; pirfenidone-treated; and para-hydroxycinnamic acid-treated, which challenged with bleomycin and received a daily oral dose of 300 and 50 mg/kg, respectively, from day 7 to day 21. Tissue pro-fibrotic and inflammatory cytokines, oxidative indicators, pulmonary histopathology, immunohistochemistry of fibrotic proteins and the assessment of gene expression by RT-qPCR were evaluated on day 22 after euthanizing animals. Pirfenidone and para-hydroxycinnamic acid managed to alleviate the fibrotic endpoints by statistically improving the weight index, histopathological score and reduced expression of fibrotic-related proteins in immune-stained lung sections, as well as fibrotic markers measured in serum samples. They also managed to alleviate tissue levels of oxidative stress and inflammatory and pro-fibrotic mediators. para-Hydroxycinnamic acid enhanced the expression of crucial genes associated with oxidative stress, inflammation and fibrosis in vivo. para-Hydroxycinnamic acid has demonstrated similar effectiveness to pirfenidone, suggesting it could be a promising treatment for fibrotic lung conditions by inhibiting the TGF-β1/Smad3 pathway or through its anti-inflammatory and antioxidant properties.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"23-42"},"PeriodicalIF":3.1,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychopharmacological treatment in patients planned for hip or knee replacement 对计划进行髋关节或膝关节置换术的患者进行精神药物治疗。

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-10 DOI: 10.1111/bcpt.14017

Simon Kornvig, Henrik Kehlet, Christoffer Calov Jørgensen, Anders Fink-Jensen, Poul Videbech, Martin Lindberg-Larsen, Kirill Gromov, Mathias Bæk Rasmussen, Manuel Josef Bieder, Claus Varnum

{"title":"Psychopharmacological treatment in patients planned for hip or knee replacement","authors":"Simon Kornvig, Henrik Kehlet, Christoffer Calov Jørgensen, Anders Fink-Jensen, Poul Videbech, Martin Lindberg-Larsen, Kirill Gromov, Mathias Bæk Rasmussen, Manuel Josef Bieder, Claus Varnum","doi":"10.1111/bcpt.14017","DOIUrl":"10.1111/bcpt.14017","url":null,"abstract":"Psychopharmacological treatment may be an independent risk factor for increased length of stay and readmission after hip and knee replacement. Thus, temporary perioperative discontinuation may be beneficial. However, little is known regarding the treatments, and not all are feasible to discontinue. Therefore, the aim of this study was to describe the treatments in terms of type, dose, duration, indication and initiating physician to assess the feasibility of temporary perioperative discontinuation. We included 482 patients planned for hip or knee replacement in psychopharmacological treatment for psychiatric disorders from 2021 to 2023 at five orthopaedic departments in Denmark. Most patients were treated with antidepressants (89%); most frequently, either selective serotonin reuptake inhibitors (SSRIs; 48%) or serotonin-norepinephrine reuptake inhibitors (SNRIs; 21%). The majority received monotherapy (70%); most frequently, an SSRI (36%) or an SNRI (12%). Most antidepressants were initiated by general practitioners (71%), and the treatments had lasted for more than a year (87%). The doses of SSRIs/SNRIs were moderate, and the most frequent indication for antidepressants was depression (77%). These results imply that temporary perioperative SSRI/SNRI discontinuation may be feasible in hip and knee replacement patients and support a future randomized controlled trial investigating the potential benefits of temporary discontinuation.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"52-59"},"PeriodicalIF":3.1,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Individual dipeptidyl peptidase-4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta-analysis 个别二肽基肽酶-4 抑制剂与 2 型糖尿病患者的急性肾损伤：系统综述和网络荟萃分析

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-05-02 DOI: 10.1111/bcpt.14014

Satoru Mitsuboshi, Makoto Morizumi, Kazumasa Kotake, Ryohei Kaseda, Ichiei Narita

{"title":"Individual dipeptidyl peptidase-4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta-analysis","authors":"Satoru Mitsuboshi, Makoto Morizumi, Kazumasa Kotake, Ryohei Kaseda, Ichiei Narita","doi":"10.1111/bcpt.14014","DOIUrl":"10.1111/bcpt.14014","url":null,"abstract":"This network meta-analysis of randomized controlled trials aimed to determine whether any individual dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of acute kidney injury (AKI). The Medical Literature Analysis and Retrieval System Online via PubMed, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were systematically searched to identify relevant studies. The primary outcome was AKI. A frequentist network meta-analysis was performed using a random-effects model to account for heterogeneity. Twenty-nine studies involving 56 117 participants were included. There were 918 cases of AKI (1.63%). The risk of bias was generally considered to be low. The only DPP-4 inhibitor that significantly increased the frequency of AKI when compared with placebo was sitagliptin (risk ratio 1.65, 95% confidence interval 1.22–2.23). However, because one study showed significant outliers in the funnel plot, in a highly heterogeneous population composed solely of patients undergoing surgery for coronary artery bypass graft, we conducted a post-hoc sensitivity analysis to exclude this study. The results showed no statistically significant difference in the risk of AKI between sitagliptin and placebo. Individual DPP-4 inhibitors do not appear to increase the risk of AKI. However, sitagliptin may be associated with AKI in patients with underlying severe cardiovascular disease.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"71-80"},"PeriodicalIF":3.1,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140826999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of quercetin in preclinical models of Parkinson's disease: A systematic review 槲皮素在帕金森病临床前模型中的作用：系统综述

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-04-29 DOI: 10.1111/bcpt.14011

Camila de Oliveira Vian, Marcelo Augusto Germani Marinho, Magno da Silva Marques, Mariana Appel Hort, Marcos Freitas Cordeiro, Ana Paula Horn

{"title":"Effects of quercetin in preclinical models of Parkinson's disease: A systematic review","authors":"Camila de Oliveira Vian, Marcelo Augusto Germani Marinho, Magno da Silva Marques, Mariana Appel Hort, Marcos Freitas Cordeiro, Ana Paula Horn","doi":"10.1111/bcpt.14011","DOIUrl":"10.1111/bcpt.14011","url":null,"abstract":"Parkinson's disease (PD) is a neurodegenerative disease that affects dopaminergic neurons, thus impairing dopaminergic signalling. Quercetin (QUE) has antioxidant and neuroprotective properties that are promising for the treatment of PD. This systematic review aimed to investigate the therapeutic effects of QUE against PD in preclinical models. The systematic search was performed in PubMed, Scopus and Web of Science. At the final screening stage, 26 articles were selected according to pre-established criteria. Selected studies used different methods for PD induction, as well as animal models. Most studies used rats (73.08%) and mice (23.08%), with 6-OHDA as the main strategy for PD induction (38.6%), followed by rotenone (30.8%). QUE was tested immersed in oil, nanosystems or in free formulations, in varied routes of administration and doses, ranging from 10 to 400 mg/kg and from 5 to 200 mg/kg in oral and intraperitoneal administrations, respectively. Overall, evidence from published data suggests a potential use of QUE as a treatment for PD, mainly through the inhibition of oxidative stress, neuroinflammatory response and apoptotic pathways.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"3-22"},"PeriodicalIF":3.1,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140809170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistence to statin treatment: A cohort study in Lithuania 他汀类药物治疗的持续性：立陶宛队列研究

IF 3.1 4区医学

Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-04-29 DOI: 10.1111/bcpt.14015

Karina Kirilova, Indrė Trečiokienė, Nomeda Bratčikovienė, Miriam Qvarnström, Björn Wettermark

{"title":"Persistence to statin treatment: A cohort study in Lithuania","authors":"Karina Kirilova, Indrė Trečiokienė, Nomeda Bratčikovienė, Miriam Qvarnström, Björn Wettermark","doi":"10.1111/bcpt.14015","DOIUrl":"10.1111/bcpt.14015","url":null,"abstract":"Cardiovascular diseases are the main causes of death, and statins can reduce the risk of major vascular events. Lithuania is among the European countries with the highest cardiovascular mortality despite a rapidly increasing use of statins. Previous reviews have shown the problem of poor patient adherence, but there are limited studies from Eastern European countries. The aim of this study was to evaluate treatment persistence in new users of statins in Lithuania and to investigate factors associated with persistence. Dispensed prescriptions from patients aged >18 years old initiated on statins in 2018–2019 were included, and data were obtained from a national health insurance fund. Persistence was assessed by the proportion of patients who still had statins dispensed 1 year after the first dispensing. Factors associated with persistence were assessed using logistic regression. A total of 104 726 patients (41.3% men) were initiated on statin treatment. Only 41% of them continued statin use 1 year after initiation. Factors associated with higher persistence rate were older age, higher dose of statin, use of other medicines and use of statins as secondary prevention. Low persistence to statin therapy needs to be recognized by healthcare workers, pharmacists and policy makers to address this problem.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 1","pages":"43-51"},"PeriodicalIF":3.1,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140827000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0